Table 1. Demographic and clinical characteristics for premenopausal and postmenopausal women at the start of antiretroviral therapy (baseline).
| Characteristic | Premenopause(N = 328) | Postmenopause(N = 55) | Total(N = 383) | p-value | |
| Age, median years (IQR) | 34 (28–40) | 52 (48–55) | 36 (30–43) | <0.001 | |
| Race/ethnicity, N (%) | White | 136 (41.5) | 28 (50.9) | 164 (42.8) | 0.239 |
| Non-white | 192 (58.5) | 27 (49.1) | 219 (57.2) | ||
| Hysterectomy, N (%) | 4 (1.2) | 10 (18.2) | 14 (3.6) | <0.001 | |
| Baseline CD4 cell count, median (IQR, cells/mm3) | 231(132–334) | 208 (85–287) | 227(127–329) | 0.14 | |
| Baseline CD4 cell count (cells/mm3), N (%) | <200 | 112 (40.3) | 24 (49.0) | 136 (41.6) | 0.495 |
| 200–500 | 149 (53.6) | 23 (46.9) | 172 (52.6) | ||
| >500 | 17(6.1) | 2 (4.1) | 19 (5.8) | ||
| Baseline HIV viral load, median (IQR, log 10 copies/mL) | 4.8 (4.1–5.4) | 4.8 (4.4–5.3) | 4.8 (4.2–5.4) | 0.18 | |
| Baseline HIV viral load (copies/mL), N (%) | 401–10,000 | 51 (20.4) | 3 (6.5) | 54 (18.2) | 0.071 |
| 10,001–100,000 | 98 (39.2) | 23 (50.0) | 121 (40.9) | ||
| >100,000 | 101 (40.4) | 20 (43.5) | 121 (40.9) | ||
| AIDS defining illness, N (%) | Yes | 68 (20.7) | 13 (23.6) | 81 (21.2) | 0.597 |
| cART regimen, N (%) | PI | 91 (27.7) | 18 (32.7) | 109 (28.5) | 0.518 |
| NNRTI | 237 (72.3) | 37 (67.3) | 274 (71.5) | ||
| Year of starting cART, N (%) | 2000–2004 | 118 (36.0) | 21 (38.2) | 139 (36.3) | 0.764 |
| 2005–2009 | 210 (64.0) | 34 (61.8) | 244 (63.7) | ||
| In clinical trial, N (%) | Yes | 125 (38.1) | 20 (36.4) | 145 (37.9) | 0.881 |
IQR, interquartile interval;
cART: Combination Antiretroviral Therapy; PI: Protease inhibitor;
NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitors.